The University of Manchester (UoM) is one of the largest single-site universities in the UK, with 40,000 students from almost every country in the world. With world-leading research and social responsibility at its heart, Manchester is a place to innovate, to lead and to make a difference.
UoM will provide clinical insight and knowledge to contribute to the management and recruitment of patients with Rheumatoid Arthritis
– Manage recruitment for the longitudinal study
– Ensure recruitment targets are reached on time and within budget
– Provide data and interpretation of digital fatigue endpoints from the QUASAR study
Target recruitment:
• Rheumatoid Arthritis – 40
• Systemic lupus erythematosus – 30
• Primary Sjögren’s syndrome – 20
• Healthy controls – 10
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.